Literature DB >> 24055218

Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011).

Ronald N Jones1, Mariana Castanheira, Bijie Hu, Yuxing Ni, Stephen S F Lin, Rodrigo E Mendes, Yao Wang.   

Abstract

Antimicrobial resistance (R) surveillance across Asia and especially in China has documented unique patterns and mechanisms. This 2011 study reports results for 2278 isolates from 12 hospitals in China (94-216 strains/site); most from bacteremia (20.4%), pneumonias (29.1%), or skin and skin structure infections (20.9%). Samples were tested by reference broth microdilution methods, interpreted by published susceptibility (S) breakpoints. The most common species were Staphylococcus aureus (343, 45.8% MRSA), Escherichia coli (EC; 288), Pseudomonas aeruginosa (PSA; 221), Klebsiella spp. (KSP; 208), acinetobacters (ACB; 178), enterobacters (155), Streptococcus pneumoniae (SPN; 154, 46.8% penicillin-S), and enterococci (ENT; 137). Among 849 Gram-positive (GP) cocci, linezolid, tigecycline (TIG), daptomycin, and vancomycin provided best antimicrobial coverage (≥99.7% S). Resistance patterns of concern were 0.3% VISA, 15.4% teicoplanin non-S coagulase-negative staphylococci, 1.5% vancomycin-R ENT (all Enterococcus faecium), 1.9% levofloxacin-R β-haemolytic streptococci, and 35.1 and 12.7% ceftriaxone-non-S rates for SPN and viridans group streptococci, respectively. For Gram-negative bacilli, R among Enterobacteriaceae was highest against β-lactams (extended spectrum β-lactamase-phenotype strains at 73.6 and 42.8% in EC and KSP, respectively; carbapenem-R was only 2.1-4.3% with KPC and IMP type enzymes detected in KSP). The widest spectrum agents were cefoperazone/sulbactam (79.5-86.1%), piperacillin/tazobactam (88.9-92.0%), TIG (98.6-100%), amikacin (AMK; 91.8-93.7%), and meropenem (95.7-97.1% S). PSA was most inhibited by AMK (90.5% S) and colistin (COL; 99.5%), with cefepime (67.9%) best among the tested β-lactams. Only COL (100% S) and TIG (MIC90, 2 μg/mL) showed significant potencies against ACB. In conclusion, R among pathogens from 12 Chinese hospitals illustrates several agents active against GP pathogens, but more serious R problems were noted among Enterobacteriaceae, PSA, and ACB. Combination treatment for the latter multidrug-R strains appears necessary, guided by local antibiograms and national surveillance results applying reference methods.
© 2013.

Entities:  

Keywords:  Carbapenemase; China; ESBLs; Reference test; Resistance; Surveillance

Mesh:

Substances:

Year:  2013        PMID: 24055218     DOI: 10.1016/j.diagmicrobio.2013.07.003

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  13 in total

1.  Development of a multiplex PCR system and its application in detection of blaSHV, blaTEM, blaCTX-M-1, blaCTX-M-9 and blaOXA-1 group genes in clinical Klebsiella pneumoniae and Escherichia coli strains.

Authors:  James O Ogutu; Qingmeng Zhang; Ying Huang; Huo Yan; Lijie Su; Bo Gao; Wenli Zhang; Jizi Zhao; Wenhui Cai; Wenjing Li; Hong Zhao; Yang Chen; Wuqi Song; Xiaobei Chen; Yingmei Fu; Fengmin Zhang
Journal:  J Antibiot (Tokyo)       Date:  2015-06-24       Impact factor: 2.649

2.  Regional resistance surveillance program results for 12 Asia-Pacific nations (2011).

Authors:  Rodrigo E Mendes; Myrna Mendoza; Kirnpal K Banga Singh; Mariana Castanheira; Jan M Bell; John D Turnidge; Stephen S F Lin; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

3.  Prevalence of multidrug resistant Gram-positive cocci in a Chinese hospital over an 8-year period.

Authors:  Ruiqin Zhang; Fengzhi Wang; Jianbang Kang; Xinchun Wang; Donghong Yin; Wen Dang; Jinju Duan
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 and 2013-14 in China.

Authors:  F Hu; D Zhu; F Wang; I Morrissey; J Wang; D Torumkuney
Journal:  J Antimicrob Chemother       Date:  2016-05       Impact factor: 5.790

5.  Dominance of CTX-M-type extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China.

Authors:  Shu Xia; Xin Fan; Zengguang Huang; Liang Xia; Meng Xiao; Rongchang Chen; Yingchun Xu; Chao Zhuo
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

6.  Healthcare Associated Infections of Methicillin-Resistant Staphylococcus aureus: A Case-Control-Control Study.

Authors:  Zhenjiang Yao; Yang Peng; Xiaofeng Chen; Jiaqi Bi; Ying Li; Xiaohua Ye; Jing Shi
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

7.  Prevalence and characteristics of extended-spectrum β-lactamase genes in Escherichia coli isolated from piglets with post-weaning diarrhea in Heilongjiang province, China.

Authors:  Guofeng Xu; Wei An; Hongdong Wang; Xiuying Zhang
Journal:  Front Microbiol       Date:  2015-10-08       Impact factor: 5.640

Review 8.  Etiologies and resistance profiles of bacterial community-acquired pneumonia in Cambodian and neighboring countries' health care settings: a systematic review (1995 to 2012).

Authors:  Sophie Goyet; Erika Vlieghe; Varun Kumar; Steven Newell; Catrin E Moore; Rachel Bousfield; Heng C Leang; Sokheng Chuop; Phe Thong; Blandine Rammaert; Sopheak Hem; Johan van Griensven; Agus Rachmat; Thomas Fassier; Kruy Lim; Arnaud Tarantola
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

Review 9.  The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials.

Authors:  Shou Zhen Wang; Jun Tao Hu; Chi Zhang; Wei Zhou; Xian Feng Chen; Liang Yan Jiang; Zhan Hong Tang
Journal:  BMJ Open       Date:  2014-06-24       Impact factor: 2.692

Review 10.  Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of China.

Authors:  Beth Lesher; Xin Gao; Yixi Chen; Zhengyin Liu
Journal:  Clinicoecon Outcomes Res       Date:  2016-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.